ElevateBio Announces Jill M. Mooney, Ph.D., Joins as Senior Vice President of Research and Development
- Jill is a strategic leader with decades of expertise in immunology, oncology, and T cell biology from drug discovery through clinical development
Cambridge, Mass., June 2, 2022 – ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, today announced that Jill M.Mooney, Ph.D., has joined as Senior Vice President of Research and Development (R&D). Jill brings more than 20 years of scientific expertise and a broad background in immuno-oncology, cell-based therapeutics for cancers, as well as synthetic biology and process development for cell therapies.
“We’re thrilled to welcome Jill to our team in this important R&D leadership role as we continue to advance our enabling technologies to develop the next-generation of cell and gene therapies,” said Mitchell H. Finer, Ph.D., President of R&D, ElevateBio. “Jill’s multi-faceted roster of experience from drug discovery through clinical development, particularly in immunology, oncology and T cell biology dovetails with ElevateBio’s R&D priorities. In this newly created role, Jill will lead the Cellular Engineering, Immunotherapy and Early Clinical Development functions and will be key in directing the ElevateBio R&D strategy.”
“ElevateBio’s impressive ecosystem of integrated technology platforms and end-to-end capabilities is well-positioned to bring innovative therapies from concept to commercialization for the entire biopharma industry,” said Jill Mooney, Ph.D. “I am very excited to be joining this dynamic team of experts and apply my experiences to build and develop our pipeline of next-generation in vivo and ex vivo therapeutics to meet the needs of patients.”
Most recently, Jill was Head of Synthorx (acquired by Sanofi Company) R&D and was responsible for the integration of the company’s platform into the Global Sanofi Large Molecule Research organization. In addition, she led the Synthorx team, managing the drug portfolio focused on immuno-oncology and immunology & inflammation indications, including the development of THOR-809 (IL-2 for autoimmune diseases) from discovery to first-in-human trials in under three years. Prior to Synthorx, Jill held various senior positions at Fate Therapeutics, Adaptive Biotechnologies and Janssen Research and Development, where her work was the subject of five patent applications. Jill received her Ph.D. in immunology from the University of Texas Southwestern Medical Center and her B.S. in Biochemistry and Biophysics from Oregon State University.
About ElevateBio:
ElevateBio is a technology-driven company built to power the development of transformative cell and gene therapies today and for many decades to come. The company has assembled industry-leading talent, built state-of-the-art facilities, and integrated diverse technology platforms, including gene editing, induced pluripotent stem cells (iPSCs), and protein, vector, and cellular engineering, necessary to drive innovation and commercialization of cellular and genetic medicines. In addition, BaseCamp is a purpose-built facility offering process innovation, process sciences, and current Good Manufacturing Practice (cGMP) manufacturing capabilities. ThroughBaseCamp and its enabling technologies, ElevateBio is focused on growing its collaborations with industry partners while also developing its own portfolio of cellular and genetic medicines. ElevateBio's team of scientists, drug developers, and company builders are redefining what it means to be a technology company in the world of drug development, blurring the line between technology and healthcare.
ElevateBio BaseCamp is located in Waltham, Mass. For more information, visit us at www.elevate.bio, or follow Elevate on LinkedIn, Twitter, or Instagram.
Investor contact:
Catherine Hu
Media contact:
Courtney Heath
ScientPR
